home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Collection of Education
/
collectionofeducationcarat1997.iso
/
HEALTH
/
MED9601.ZIP
/
M9610766.TXT
< prev
next >
Wrap
Text File
|
1996-01-30
|
1KB
|
23 lines
Document 0766
DOCN M9610766
TI Progress in anti-HIV structure-based drug design.
DT 9601
AU Gait MJ; Karn J; MRC Laboratory of Molecular Biology, Cambridge, UK.
SO Trends Biotechnol. 1995 Oct;13(10):430-8. Unique Identifier : AIDSLINE
MED/96030281
AB The course of drug development for the treatment of HIV-1 infection and
AIDS is being revolutionized by high-resolution structures of essential
viral proteins. We survey the impact on drug design of the recently
elucidated structural knowledge of two essential enzymes, reverse
transcriptase and protease, and three new targets, the viral integrase
and the gene regulatory protein-RNA interactions, Tat-TAR and Rev-RRE.
DE Antiviral Agents/*PHARMACOLOGY *Drug Design Drug Resistance DNA
Nucleotidyltransferases/ANTAGONISTS & INHIB Human HIV/*DRUG
EFFECTS/GENETICS HIV Protease Inhibitors/PHARMACOLOGY Reverse
Transcriptase Inhibitors/PHARMACOLOGY Virus Replication/DRUG EFFECTS
JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).